Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of High-dose Treatment With the Immunomodulator Interferon-α-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma.

NCT00749684 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT00749684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00749684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of High-dose Treatment With the Immunomodulator Interferon-α-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma.
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Observational
Overall status
Completed
Start date
December 31, 1996
Completion date
September 30, 2009
Enrollment
138 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma